Skip to content
Open access

Intracellular screening of nanobodies reveals an intrabody that inhibits ITCH E3 ubiquitin ligase

Aug 2026 · bioRxiv · 0 citations · 37 references
Biology

TL;DR

Traditional in vitro screening of a nanobody library combined with an intracellular bioluminescence resonant energy transfer (BRET) proximity sensor approach for sequence down-selection can yield strong in vitro binders that also perform well as intrabodies, in this case capable of binding to and inhibiting the enzymatic activity of ITCH E3 ubiquitin ligase in human cells.

Abstract

Nanobodies are a class of small, monomeric camelid antibody fragments that can bind target antigens with high affinity and specificity. Their small size, structural simplicity, and limited reliance on disulfide bonding makes them attractive for intracellular expression for labeling and perturbing cellular processes in live cells. However, screening campaigns carried out exclusively in vitro often yield antigen binders that fail to perform well in live cells due to low expression, misfolding, or mistargeting. We demonstrate that traditional in vitro screening of a nanobody library combined with an intracellular bioluminescence resonant energy transfer (BRET) proximity sensor approach for sequence down-selection can yield strong in vitro binders that also perform well as intrabodies, in this case capable of binding to, and inhibiting the enzymatic activity of, ITCH E3 ubiquitin ligase in human cells. This strategy allows a more direct and scalable path toward intrabody discovery.

Read PDF

Similar papers

Review Open access Sep 2026

Smaller is better: nanobodies meet NMR.

This review summarizes recent advances in nanobody engineering for NMR studies, including the synthetic nanobodies, highlights the nanobodies' role in overcoming size and stability limitations, and discusses future directions for integrating nanobodies into emerging NMR methodologies, with an emphasis on protein dynami...

Oleg Y. Dmitriev · 0 citations
Aug 2026

Discovery of Cbl-b Targeting Cyclic Peptide Ligands by Phage Display.

Cbl-b is a RING-type E3 ubiquitin ligase and intracellular immune checkpoint that negatively regulates immune-cell activation. However, ligand discovery for Cbl-b remains limited, largely because the RING-type E3 ubiquitin ligase is regulated by shallow and extended protein-protein interaction interfaces that are diffi...

Xiao-Qin Yang, Ming Wei, Wei-Kang Zhai et al. · 0 citations
Review Oct 2026

Nanobodies as Versatile Next-Generation Biologics.

Nanobodies, also known as single-domain antibodies or variable domains of heavy-chain-only antibodies (VHHs), are the antigen-binding domains derived from heavy-chain-only antibodies that naturally occur in camelids. Since their discovery in the early 1990s, Nanobodies have attracted significant attention in the fields...

S. Muyldermans, J. Steyaert · 0 citations
Open access Aug 2026

Harnessing the E3 Ligase KLHL12 for Tumor-Selective Protein Degradation.

KLHL12 is identified as a potentially tumor-selective E3 ligase and the development of the first-in-class KLHL12-recruiting PROTACs are reported, which established KLHL12 as a promising tumor‑selective E3 ligase and provided a KLHL12-recruiting PROTAC platform for cancer therapy.

Shicheng Xu, Xian Zhang, Shun-Bo Hu et al. · 0 citations
Open access Aug 2026

Multimerization of a rationally designed nanobody for enhanced avidity toward Aβ42 oligomers

Alzheimer's disease affects tens of millions of people worldwide and is associated with the self‐assembly of the Aβ42 peptide into amyloid aggregates. Among the species formed during this process, soluble oligomeric intermediates are the most closely linked to neurotoxicity and are therefore an attractive target for bo...

Magdalena Nowinska, Elijah Suh, C. Mogilevsky et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.